Rubicon Research Limited has officially notified the stock exchanges on April 15, 2026, regarding its strategic move to acquire an 85% stake in Arinna Lifesciences Limited. This acquisition, valued at an enterprise value of INR 200 Crores, will result in Arinna Lifesciences becoming a subsidiary of Rubicon. The transaction involves a cash consideration of approximately INR 175.92 Crores for the secondary acquisition of shares at a price of roughly INR 158.53 per share.

The acquisition is a calculated step for Rubicon Research to strengthen its presence in the Indian domestic formulations market, specifically targeting the Central Nervous System (CNS) therapeutic segment. Arinna Lifesciences, headquartered in Ahmedabad, is a branded pharmaceutical marketing firm with a robust network of over 4,000 prescribers across India. By integrating Arinna’s sales and distribution infrastructure, Rubicon intends to leverage its existing intellectual property and chronic product portfolio to reach a wider patient base in India. The deal is expected to conclude within one month from the signing of the transaction documents.

Rubicon Research Limited is a pharmaceutical player focused on innovation, quality, and care, originally established in 1999. The company has shown significant growth in its international operations, recently scaling its US revenues by over 32 times between FY15 and FY25. In addition to this major acquisition, Rubicon has been active in expanding its global footprint, such as incorporating a wholly owned subsidiary, AdvaGen S A Company, in Saudi Arabia in January 2026. The company’s portfolio includes a strong pipeline of specialty products and drug-device combinations.

For the quarter ended December 31, 2025 (Q3 FY26), Rubicon Research reported a stellar performance with revenue reaching INR 479.32 Crores, representing a 52.7% increase compared to the INR 313.89 Crores recorded in the same period of the previous year. Net profit for the same quarter surged by 91.23% YoY to INR 72.80 Crores. On a quarter-on-quarter basis, revenue grew by 16.14% from INR 412.72 Crores in September 2025, while net profit saw a significant 35.19% jump. The company maintains a healthy shareholding structure as of December 2025, with promoters holding 59.99%, Foreign Institutional Investors (FIIs) at approximately 8.00%, and Mutual Funds accounting for 6.61%. Famous institutional investors in the company’s target entity, Arinna Lifesciences, have previously included Czar Capital and Motilal Oswal Private Equity.